Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | STS | P08842 | 2/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6134609 | 0.85 | NOTUM (0.50) | LMNAMAPK1HTTRAB9ASTS | |
| SCHEMBL1473470 | 0.85 | HSD11B1 (0.40) | RAB9ASTSHSD11B1ALDH1A1CREBBP | |
| SCHEMBL881308 | 0.84 | CA12 (0.50) | LMNAMAPK1HTTRAB9AALDH1A1 | |
| SCHEMBL9300174 | 0.84 | AKR1C3 (0.44) | STSHSD11B1KIF11CREBBPAKR1C3 | |
| SCHEMBL4705593 | 0.84 | AKR1C3 (0.48) | HSD11B1AKR1C3AKR1C2 | |
| SCHEMBL6139341 | 0.84 | ESRRA (0.46) | MAPK1STSHSD11B1ALDH1A1CREBBP | |
| SCHEMBL32665224 | 0.83 | LMNA (0.47) | LMNAMAPK1HTTRAB9ASTS | |
| SCHEMBL2311506 | 0.82 | RARA (0.43) | STSHSD11B1KIF11CREBBPAKR1C3 | |
| SCHEMBL227343 | 0.82 | RAB9A (0.50) | LMNAMAPK1HTTRAB9ASTS | |
| SCHEMBL6645216 | 0.81 | ALDH1A1 (0.40) | HTTSTSHSD11B1ALDH1A1CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3210969-B1 | KCNQ2-5 CHANNEL ACTIVATOR | ONO PHARMACEUTICAL CO (JP) | 2021-04-28 | — | — | EP | disclosed |
| CN-107108485-B | KCNQ 2-5 channel activator | 小野药品工业株式会社 | 2020-06-12 | — | — | CN | disclosed |
| US-10676438-B2 | KCNQ2-5 channel activator | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-06-09 | — | — | US | disclosed |
| US-20200157050-A1 | KCNQ2-5 CHANNEL ACTIVATOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-05-21 | — | — | US | disclosed |
| US-10570093-B2 | — | — | 2020-02-25 | — | — | US | disclosed |
| US-10196358-B2 | KCNQ2-5 channel activator | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-02-05 | — | — | US | disclosed |
| US-20180346422-A1 | KCNQ2-5 CHANNEL ACTIVATOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-12-06 | — | — | US | disclosed |
| US-20170334855-A1 | KCNQ2-5 CHANNEL ACTIVATOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-11-23 | — | — | US | disclosed |
| US-9809544-B2 | KCNQ2-5 channel activator | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-11-07 | — | — | US | disclosed |
| EP-3210969-A1 | KCNQ2-5 CHANNEL ACTIVATOR | ONO Pharmaceutical Co., Ltd. (JP) | 2017-08-30 | — | — | EP | disclosed |
| US-20170217888-A1 | KCNQ2-5 CHANNEL ACTIVATOR | ONO PHARMACEUTICAL CO., LTD (JP) | 2017-08-03 | — | — | US | disclosed |
| US-6951876-B2 | Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents | PFIZER, INC. (US) | 2005-10-04 | — | — | US | disclosed |
| US-6603008-B1 | Inhibit the biosynthesis of prostaglandins by intervention of the action of the enzyme cyclooxygenase on arachidonic acid | PFIZER INC. | 2003-08-05 | — | — | US | disclosed |
| US-20030144280-A1 | Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents | PFIZER INC. (US) | 2003-07-31 | — | — | US | disclosed |
| EP-1104760-B1 | Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents | PFIZER PROD INC (US) | 2003-03-12 | — | — | EP | disclosed |
| EP-1104760-A1 | Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents | Pfizer Products Inc. (US) | 2001-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570093-B2 | — | KCNQ5, KCNQ2, KCNQ1 | LMNA 1050/4885MAPK1 2365/4885HTT 1217/4885 |
| US-20170334855-A1 | KCNQ2-5 CHANNEL ACTIVATOR | KCNQ5, KCNQ2, KCNQ1 | LMNA 850/4885MAPK1 1573/4885HTT 1916/4885 |
| US-20170217888-A1 | KCNQ2-5 CHANNEL ACTIVATOR | KCNQ5, KCNQ2, KCNQ1 | LMNA 850/4885MAPK1 1573/4885HTT 1916/4885 |
| US-20200157050-A1 | KCNQ2-5 CHANNEL ACTIVATOR | KCNQ5, KCNQ2, KCNQ1 | LMNA 850/4885MAPK1 1573/4885HTT 1916/4885 |
| US-20180346422-A1 | KCNQ2-5 CHANNEL ACTIVATOR | KCNQ5, KCNQ2, KCNQ1 | LMNA 850/4885MAPK1 1573/4885HTT 1916/4885 |
| US-10676438-B2 | KCNQ2-5 channel activator | KCNQ5, KCNQ2, KCNQ1 | LMNA 850/4885MAPK1 1573/4885HTT 1916/4885 |
| US-10196358-B2 | KCNQ2-5 channel activator | KCNQ5, KCNQ2, KCNQ1 | LMNA 850/4885MAPK1 1573/4885HTT 1916/4885 |
| US-20030144280-A1 | Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents | PTGS1, PTGS2, SULT2A1 | LMNA 4720/4885MAPK1 366/4885HTT 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.